Background: The Medicare Bundled Payments for Care Improvement (BPCI) program reimburses 90-day care episodes post-hospitalization. COPD is a leading cause of early readmissions making it a target for value-based payment reform.

Objective: Evaluate the financial impact of a COPD BPCI program.

Design, Participants, Interventions: A single-site retrospective observational study evaluated the impact of an evidence-based transitions of care program on episode costs and readmission rates, comparing patients hospitalized for COPD exacerbations who received versus those who did not receive the intervention.

Main Measures: Mean episode costs and readmissions.

Key Results: Between October 2015 and September 2018, 132 received and 161 did not receive the program, respectively. Mean episode costs were below target for six out of eleven quarters for the intervention group, as opposed to only one out of twelve quarters for the control group. Overall, there were non-significant mean savings of $2551 (95% CI: - $811 to $5795) in episode costs relative to target costs for the intervention group, though results varied by index admission diagnosis-related group (DRG); there were additional costs of $4184 per episode for the least-complicated cohort (DRG 192), but savings of $1897 and $1753 for the most complicated index admissions (DRGs 191 and 190, respectively). A significant mean decrease of 0.24 readmissions per episode was observed in 90-day readmission rates for intervention relative to control. Readmissions and hospital discharges to skilled nursing facilities were factors of higher costs (mean increases of $9098 and $17,095 per episode respectively).

Conclusions: Our COPD BPCI program had a non-significant cost-saving effect, although sample size limited study power. The differential impact of the intervention by DRG suggests that targeting interventions to more clinically complex patients could increase the financial impact of the program. Further evaluations are needed to determine if our BPCI program decreased care variation and improved quality of care.

Primary Source Of Funding: This research was supported by NIH NIA grant #5T35AG029795-12.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506991PMC
http://dx.doi.org/10.1007/s11606-023-08249-6DOI Listing

Publication Analysis

Top Keywords

episode costs
16
bpci program
12
bundled payments
8
payments care
8
care improvement
8
financial impact
8
copd bpci
8
program episode
8
readmission rates
8
intervention group
8

Similar Publications

Background: The clinical manifestations of sickle cell disease (SCD) result in significant morbidity and healthcare costs. The effect of weather as a risk factor for the development of vaso-occlusive episodes (VOEs) has been previously studied, although with variable results. The aim of our retrospective, nationwide study was to determine the association between weather patterns and pediatric VOE and acute chest syndrome (ACS).

View Article and Find Full Text PDF

Objective: To estimate incidence and healthcare costs and mortality associated with infection (CDI) among adults <65 years old.

Design: Retrospective cohort study.

Patients: First CDI episodes among commercially insured US patients 18-64 years old were identified from a large claims database.

View Article and Find Full Text PDF

Koopman learning with episodic memory.

Chaos

January 2025

AIMdyn, Inc., Santa Barbara, California 93101, USA.

Koopman operator theory has found significant success in learning models of complex, real-world dynamical systems, enabling prediction and control. The greater interpretability and lower computational costs of these models, compared to traditional machine learning methodologies, make Koopman learning an especially appealing approach. Despite this, little work has been performed on endowing Koopman learning with the ability to leverage its own failures.

View Article and Find Full Text PDF

Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States.

J Manag Care Spec Pharm

January 2025

Global Value and Real-World Evidence, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ.

Background: Bipolar disorder is a severe recurrent, episodic psychiatric condition with a worldwide prevalence of approximately 1%, affecting more than 5 million adults in the United States in 2020. A subtype, bipolar I disorder (BP-I), which accounts for approximately one-quarter of cases, is associated with impairments in psychosocial functioning and quality of life. Recommended treatment options include daily oral, or long-acting injectable, antipsychotics, including the aripiprazole once every month formulation, which has been shown to improve adherence compared with oral treatments.

View Article and Find Full Text PDF

Infections and Factors Associated with Recurrence.

Infect Dis Clin Microbiol

December 2024

Department of Medical Microbiology, Giresun University School of Medicine, Giresun, Türkiye.

Objective: is one of the leading causes of antibiotic-associated diarrhea. Recurrent infection (rCDI) is significant because of prolonged hospital stays, morbidity, and additional costs. Our study aimed to examine the characteristics of infections and investigate factors associated with recurrence.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!